Ajanta Pharma Ltd (AJANTPHARM)
₹3,508.80
Mkt cap
₹43,846 Cr
P/E ratio
34.70
P/B
9.02
Div yield
0.91%
ROE
27.10%
ROCE
34.50%
EPS (TTM)
₹101.12
Book value
₹389
52W range
2,382–3,796
Sector
Healthcare
Price history
Previous close
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
NSE AJANTPHARMBSE 532331
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−7.57% from high₹3,509
₹2,382+47.30% from low₹3,796
Current
₹3,508.80
Prev close
₹3,459.70
Day
+1.42%
Price performance
1D
+0.07%
1W
+5.42%
1M
−2.68%
3M
+0.74%
6M
+23.46%
1Y
+43.38%
YTD
+18.97%
Financials
Revenue, profit & margin
P/E ratio
34.7×
AJANTPHARM is 2% above the sector median of 34.0×
AJANTPHARM34.7×
Sector median34.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 | 1,794 | |
| Expenses | 738 | 791 | 776 | 815 | 875 | 825 | 873 | 951 | 1,026 | 993 | 1,088 | 1,202 | 1,247 | |
| Operating Profit | 291 | 314 | 278 | 330 | 311 | 321 | 297 | 351 | 328 | 382 | 333 | 424 | 548 | |
| OPM % | 28% | 28% | 26% | 29% | 26% | 28% | 25% | 27% | 24% | 28% | 23% | 26% | 31% | |
| Other Income | 21 | 14 | 36 | 26 | 19 | 30 | 18 | 26 | 59 | 25 | 61 | 71 | 37 | |
| Interest | 2 | 2 | 2 | 1 | 6 | 8 | 6 | 5 | 3 | 5 | 2 | 3 | 2 | |
| Depreciation | 34 | 34 | 34 | 34 | 34 | 36 | 40 | 41 | 43 | 44 | 45 | 44 | 48 | |
| Profit before tax | 276 | 291 | 278 | 322 | 290 | 307 | 269 | 331 | 341 | 359 | 347 | 447 | 535 | |
| Tax % | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% | 27% | |
| Net Profit | 195 | 210 | 203 | 246 | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 | 388 | |
| EPS in Rs | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 | 21.91 | 21.35 | 26.75 | 31.06 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +1.68% · closed higher next day 43 of last 63
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 31 Jan '24◦ | 2 May '24◦ | 30 Jul '24◦ | 29 Oct '24 | 30 Jan '25◦ | 30 Apr '25◦ | 28 Jul '25 | 3 Nov '25 | 30 Jan '26 | 5 May '26 | 30 Jul '26 | 30 Oct '26 |
| Earnings day | +0.32% | +6.71% | +6.50% | +0.06% | +0.66% | −4.47% | −0.62% | +3.01% | +3.23% | −0.11% | +1.17% | +0.07% |
| +1 day | −0.27% | +8.08% | +10.35% | +2.53% | +1.56% | −4.42% | +1.40% | +5.90% | +3.38% | +6.74% | +2.02% | — |
| +5 days | +1.32% | +6.42% | +16.16% | +6.61% | +0.82% | −6.22% | −5.32% | +4.56% | +5.86% | +6.58% | +2.18% | — |
| +15 days | −2.50% | +8.44% | +23.42% | +1.28% | −0.49% | −4.85% | −2.91% | +1.78% | +9.07% | +6.77% | +7.72% | — |
| +30 days | −2.39% | +6.47% | +34.01% | −3.94% | −3.74% | −2.66% | −6.84% | +5.31% | +9.62% | +6.16% | +3.64% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202663.47%Promoter
Promoters63.47%0.02
FIIs7.62%0.06
DIIs21.94%0.14
Public6.96%0.07
Government0.00%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Ajanta Pharma | ₹3,508.80 | 34.72 | 43,846 | 0.91% | 388 | +49.18% | 1,794 | +32.53% | 34.51% |
| Median: 158 Co. | ₹426.38 | 34.03 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts55
RECOct 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptJul 2025PPTJul 2025TranscriptApr 2025PPTApr 2025RECApr 2025TranscriptFeb 2025PPTFeb 2025TranscriptOct 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024TranscriptJan 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Oct - Q2FY2027 earnings call audio recording uploaded on 30 October 2026.Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2026. 30 Oct - Ajanta Pharma reported Q2 FY2027 results: revenue up 33%, PAT up 49%; conference call at 16:00 IST.Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2026. 30 Oct - Ajanta Pharma reported Q2 FY2027 consolidated PAT up 49% to Rs 388 crore; conference call at 16:00 IST.Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 21 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Oct - Pls find enclosed Earnings Conference Call Intimation.